Prevention of tuberculosis in patients treated with tumour necrosis factor antagonists

Maria Korzeniewska-Koseła

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2010
vol. 48

Send email

Copy url:

abstract:

Short communication

Prevention of tuberculosis in patients treated with tumour necrosis factor antagonists

Maria Korzeniewska-Koseła

Reumatologia 2010; 48, 1: 4-13

Online publish date: 2010/04/09

View full text Get citation

Tumour necrosis factor inhibition increases the risk of tuberculosis. Active tuberculosis should be excluded and screening for latent tuberculosis infection should be done before commencement of treatment with tumour necrosis factor antagonists. Chest radiography and interferon-γ-release assay (IGRA) should be performed; medical history to screen for TB risk factors should be taken. IGRA use will help to reduce over-use and under-use of preventive treatment in candidates for TNF antagonist therapy. If a patient is diagnosed with latent TB infection, chemopreventive treatment should be introduced.

keywords:

TNF antagonists, tuberculosis, latent tuberculosis infection, chemoprophylaxis

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI